NVZMF (Novonesis (Novozymes) B) Current Deferred Revenue : $0 Mil (As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Novonesis (Novozymes) B's current deferred revenue for the quarter that ended in Mar. 2025 was $0 Mil.

Novonesis (Novozymes) B Current Deferred Revenue Historical Data

The historical data trend for Novonesis (Novozymes) B's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Current Deferred Revenue Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Deferred Revenue

Get a 7-Day Free Trial

Novonesis (Novozymes) B Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25
Current Deferred Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Novonesis (Novozymes) B Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMF) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NSISBc:UK 0Q4U:UK NSIS B:Denmark NZM:Germany NZM:Germany NZM2:Germany NZM2:Germany NZYM:Austria

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.